ABSTRACT OBJECTIVES This study sought to evaluate the effect of macitentan on hospitalization of patients with symptomatic pulmonary arterial hypertension (PAH).
P ulmonary arterial hypertension (PAH)
is a progressive, life-threatening disease that affects the pulmonary vasculature (1) . The disease is characterized by sustained elevation of pulmonary vascular resistance ultimately resulting in right heart failure due to the inability of right ventricular contractility to adapt to the increasing afterload. Mortality rates in PAH are still high despite improvements in patient survival since the introduction of PAH-specific therapies (2-4).
The progressive nature of PAH means that morbidity events associated with the disease and the initiation of new PAH therapies can require hospitalization of patients (5) . Hospitalization has a negative impact on patients' quality of life and an adverse effect on the lives of their caregivers and represent a substantial health care burden (6) . Data from the REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) registry showed that patients who were hospitalized for PAH were more likely to be rehospitalized and had worse survival at 3 years than those who were not hospitalized (7) . Despite this considerable impact, information describing the effect of PAH-specific therapies on hospitalization is limited. Most randomized controlled trials in PAH have included PAH-related hospitalization as a component of secondary or exploratory "time to clinical worsening" endpoints and have captured only a relatively low number of hospitalizations due to low numbers of patients and short durations (12 to 24 weeks) (8) (9) (10) (11) (12) (13) (14) (15) (16) . Therefore, it has not been possible to determine reliable annual rates of hospitalization from these studies.
Macitentan is a novel dual endothelin receptor antagonist with sustained receptor binding and enhanced tissue penetration (17, 18) . In the first eventdriven, randomized controlled outcomes study in PAH, the SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary arterial Hypertension to Improve cliNical outcome) trial, the risk of morbidity and mortality events (the primary endpoint) was significantly reduced by 30% with 3 mg of macitentan (p ¼ 0.01) and by 45% with 10 mg of macitentan (p<0.001) compared to that with placebo (19) . A composite secondary endpoint of "death due to PAH or hospitalization for PAH" was included in SERAPHIN, and the risk of such events was significantly reduced by 33% with 3 mg of macitentan (p ¼ 0.01) and by 50% with 10 mg of macitentan (p < 0.001) compared with those with placebo (19 Local institutional review boards or independent ethics committees approved the protocol, and written informed consent was obtained from all patients.
STUDY DESIGN. SERAPHIN was a multicenter, double-blind, randomized, placebo-controlled, eventdriven, phase III trial (NCT00660179). The study design was described in detail previously (19) . Briefly, per patient-year was also analyzed, as was the total number of hospital days per patient-year. In addition, the effect of macitentan on the time to first non-PAH-related hospitalization was also assessed by post-hoc analysis of all patients, and the causes of these hospitalizations were examined. Whether PAH was the cause of hospitalization was determined at the discretion of the investigator.
STATISTICAL METHODS. All time-to-event endpoints occurring in the intention-to-treat (all-randomized) set were analyzed using the Kaplan-Meier method and the log-rank test. Patients who stopped blinded treatment without an event were censored at the time of treatment discontinuation. Treatment effects were expressed in terms of risk reductions and were presented using hazard ratios (HRs) and 95% confidence intervals (CIs) calculated from Cox regression models.
Exploratory subgroup analyses on the basis of pre- and, to a lesser extent, the upper respiratory tract. toxins. Abbreviation as in Figure 2 .
Macitentan Effect on Hospitalizations
These infections were more frequent in the placebo and 3-mg macitentan arms than in the 10-mg arm The reduced rates of all-cause and PAH-related hospitalizations observed in the macitentan treatment arms also resulted in decreases in the number of annual hospital days experienced by these patients. This duration is more than 4 times longer than that of previous trials of PAH-specific agents. These data provide a comprehensive view of how macitentan affects hospitalizations over a prolonged period of time. A potential limitation for the PAH-related hospitalizations is that they were judged to be related or not related to PAH by the investigator.
Nevertheless, a substantial proportion of PAH-related hospitalizations occurred in conjunction with primary endpoint events that were adjudicated by a clinical event committee and, therefore, provide reassurance that the judgment of the investigators was appropriate. In addition, the fact that the favorable treatment effect of macitentan is driven by the effect on PAH-related hospitalization validates the assessment of causality made by the investigator.
Another point to consider is that there are variations in hospitalization practices from country to country.
Although the results in the Online material outline differences between regions, the results should be interpreted with caution, as the analyses are exploratory, subject to small sample size and low numbers of events, and are not adjusted for multiple comparisons.
CONCLUSIONS
In conclusion, 10 mg of macitentan significantly reduced the risk and rate of hospitalization for any cause, in addition to the duration of hospital stay.
These treatment effects were driven by reductions in the risk and rate of PAH-related hospitalization.
Importantly, the reduction in PAH-related hospitalization was not offset by an increase in hospitalization for other causes. Overall, these findings provide further evidence of improved long-term outcomes in PAH patients treated with macitentan.
ACKNOWLEDGMENTS Medical writing was provided by Liesje Quine, PhD, and Lisa Thomas, PhD, Elements
Communications, Ltd., Westerham, United Kingdom, and funded by Actelion Pharmaceuticals Ltd.
